Literature DB >> 4044164

Patterns of herpes simplex keratitis in inbred mice.

R D Stulting, J C Kindle, A J Nahmias.   

Abstract

The authors have investigated the course of herpes simplex type 1 (HSV) keratitis in three different inbred strains of mice infected with four different HSV isolates. Severity of ocular disease and mortality is dependent upon both the virus isolate and the host strain. In particular, the likelihood of progression from self-limited dendritic keratitis to severe necrotizing stromal keratitis varies markedly among the virus-host strain combinations tested. When mice from strains resistant to stromal disease are crossed with mice from strains susceptible to stromal disease, the F1 offspring are resistant, suggesting that the gene(s) controlling resistance is dominant. Corneal stromal keratocytes and embryo fibroblasts from inbred mice differ significantly in their ability to support the replication of HSV in vitro. HSV replicates more efficiently in vitro in keratocytes from mice susceptible to stromal keratitis than it does in keratocytes from mice resistant to stromal keratitis. These findings provide evidence in an animal model for both virus- and host-related mechanisms that determine susceptibility to stromal keratitis.

Entities:  

Mesh:

Year:  1985        PMID: 4044164

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Sequence variation in the herpes simplex virus U(S)1 ocular virulence determinant.

Authors:  Aaron W Kolb; Timothy R Schmidt; David W Dyer; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-28       Impact factor: 4.799

2.  Using HSV-1 genome phylogenetics to track past human migrations.

Authors:  Aaron W Kolb; Cécile Ané; Curtis R Brandt
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

3.  Multiplex sequencing of seven ocular herpes simplex virus type-1 genomes: phylogeny, sequence variability, and SNP distribution.

Authors:  Aaron W Kolb; Marie Adams; Eric L Cabot; Mark Craven; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

4.  Mapping of genes involved in murine herpes simplex virus keratitis: identification of genes and their modifiers.

Authors:  Kazumi Norose; Akihiko Yano; Xiang-Ming Zhang; Elizabeth Blankenhorn; Ellen Heber-Katz
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 5.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

6.  Recombination Analysis of Herpes Simplex Virus 1 Reveals a Bias toward GC Content and the Inverted Repeat Regions.

Authors:  Kyubin Lee; Aaron W Kolb; Yuriy Sverchkov; Jacqueline A Cuellar; Mark Craven; Curtis R Brandt
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

7.  Recombinants are isolated at high frequency following in vivo mixed ocular infection with two avirulent herpes simplex virus type 1 strains.

Authors:  R L Kintner; R W Allan; C R Brandt
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells.

Authors:  K S Dingwell; C R Brunetti; R L Hendricks; Q Tang; M Tang; A J Rainbow; D C Johnson
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

9.  The pathogenesis of herpetic ocular disease in the guinea pig.

Authors:  A H Wander; H C Bubel; S G McDowell
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

10.  Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.

Authors:  K Olson; P Macias; S Hutton; W A Ernst; G Fujii; J P Adler-Moore
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.